#FGDebate: Should we focus on detecting patients at risk of liver disease in the community?
作者信息
Abeysekera Kushala Wm, Shearer Jessica, Tavabie Oliver D, Dillon John F, Rowe Ian A
机构信息
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Leeds Liver Unit, St James's University Hospital, Leeds, UK.
出版信息
Frontline Gastroenterol. 2022 Dec 1;14(4):343-345. doi: 10.1136/flgastro-2022-102330. eCollection 2023.
Abstract
摘要
相似文献
1
#FGDebate: Should we focus on detecting patients at risk of liver disease in the community?#FG 辩论：我们是否应该专注于在社区中检测有肝病风险的患者？
Frontline Gastroenterol. 2022 Dec 1;14(4):343-345. doi: 10.1136/flgastro-2022-102330. eCollection 2023.
2
[Research progress of non-invasive examination in the screening of chronic liver disease among the general community population].
Zhonghua Gan Zang Bing Za Zhi. 2021 Sep 20;29(9):825-829. doi: 10.3760/cma.j.cn501113-20210826-00430.
3
A discrete choice experiment to elicit preferences for a liver screening programme in Queensland, Australia: a mixed methods study to select attributes and levels.采用离散选择实验方法在澳大利亚昆士兰州获取人们对肝脏筛查项目的偏好：一项选择属性和水平的混合方法研究
BMC Health Serv Res. 2023 Sep 5;23(1):950. doi: 10.1186/s12913-023-09934-2.
4
Time to focus on chronic liver diseases in the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.是时候关注社区中的慢性肝病了：基层医疗肝病学工具、护理途径及报销机制综述
J Hepatol. 2023 Mar;78(3):663-671. doi: 10.1016/j.jhep.2022.10.010. Epub 2022 Oct 23.
5
Community screening identifies undiagnosed chronic liver disease in high-risk populations.社区筛查可在高危人群中发现未确诊的慢性肝病。
J Gastroenterol Hepatol. 2021 Aug;36(8):2255-2260. doi: 10.1111/jgh.15473. Epub 2021 Mar 17.
6
Detecting chronic liver disease: are liver function tests the solution?检测慢性肝病：肝功能检查是解决之道吗？
Br J Hosp Med (Lond). 2020 Feb 2;81(2):1-8. doi: 10.12968/hmed.2019.0308. Epub 2020 Feb 19.
7
Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening.用于慢性肝病中肝细胞癌筛查的扩散加权磁共振成像：与超声筛查的直接比较。
J Med Imaging Radiat Oncol. 2017 Feb;61(1):34-39. doi: 10.1111/1754-9485.12513. Epub 2016 Aug 25.
8
Albuminuria in a remote South Australian Aboriginal community: results of a community-based screening program for renal disease.南澳大利亚一个偏远原住民社区的蛋白尿：一项基于社区的肾脏疾病筛查项目结果
Rural Remote Health. 2003 Jan-Jun;3(1):156. Epub 2003 Feb 8.
9
Population screening for neonatal liver disease: potential for a community-based programme.新生儿肝病的人群筛查：基于社区项目的潜力。
J Med Screen. 2003;10(3):112-6. doi: 10.1177/096914130301000303.
10
Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease.血清丙氨酸氨基转移酶上正常范围上限值可用于识别慢性肝病风险人群。
Liver Int. 2012 Jul;32(6):937-44. doi: 10.1111/j.1478-3231.2011.02749.x. Epub 2012 Jan 20.
引用本文的文献
1
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening.用于识别需要进行肝病筛查的高危个体的循证标准。
Hepatol Commun. 2025 Mar 21;9(4). doi: 10.1097/HC9.0000000000000679. eCollection 2025 Apr 1.
本文引用的文献
1
Identification of liver disease: why and how.肝病的识别：原因与方法。
Frontline Gastroenterol. 2022 Jan 24;13(5):367-373. doi: 10.1136/flgastro-2021-101833. eCollection 2022.
2
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review.社区途径用于慢性肝病的早期检测和风险分层：叙事系统评价。
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):770-780. doi: 10.1016/S2468-1253(22)00020-6. Epub 2022 May 5.
3
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.人群中 FIB-4 和 NAFLD 纤维化评分对筛查肝纤维化的准确性低。
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2567-2576.e6. doi: 10.1016/j.cgh.2021.12.034. Epub 2021 Dec 29.
4
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.欧洲肝脏研究学会-《柳叶刀》肝脏委员会：保护下一代欧洲人免受肝脏疾病并发症和过早死亡的影响。
Lancet. 2022 Jan 1;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3. Epub 2021 Dec 2.
5
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.EASL 临床实践指南：非侵入性检测评估肝脏疾病严重程度和预后——2021 更新版。
J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21.
6
Impact of minimum unit pricing on alcohol purchases in Scotland and Wales: controlled interrupted time series analyses.苏格兰和威尔士最低单位定价对酒类购买量的影响：对照中断时间序列分析。
Lancet Public Health. 2021 Aug;6(8):e557-e565. doi: 10.1016/S2468-2667(21)00052-9. Epub 2021 May 28.
7
Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review With Meta-analysis.基于肝损伤生物标志物或非侵入性肝纤维化检测的建议是否会影响高危饮酒行为：系统评价和荟萃分析。
Alcohol Alcohol. 2021 Feb 24;56(2):185-200. doi: 10.1093/alcalc/agaa143.
8
The Development and Implementation of a Commissioned Pathway for the Identification and Stratification of Liver Disease in the Community.社区肝病识别与分层委托路径的制定与实施
Frontline Gastroenterol. 2020 Feb 10;11(2):86-92. doi: 10.1136/flgastro-2019-101177. Epub 2019 Jun 26.
9
Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.非酒精性脂肪肝社区路径中 FIB-4、ELF 和 fibroscan 的成本比较分析。
BMC Gastroenterol. 2019 Jul 11;19(1):122. doi: 10.1186/s12876-019-1039-4.
10
Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care.智能肝功能检测(iLFT)：在初级保健中自动诊断和分期肝病的试验。
J Hepatol. 2019 Oct;71(4):699-706. doi: 10.1016/j.jhep.2019.05.033. Epub 2019 Jun 19.
Zotero 插件